# A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

> **NCT00067730** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 7 (actual)

## Conditions studied

- Sepsis
- Hematologic Neoplasms
- Hematopoietic Stem Cell Transplantation
- Infection

## Interventions

- **DRUG:** Drotrecogin Alfa (activated)

## Key facts

- **NCT ID:** NCT00067730
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2003-10
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2007-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00067730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00067730, "A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00067730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*